NUCOREBIO · EXCLUSIVE LICENSEE REFERENCE GUIDE

Formula Modification Rights Guide

What Exclusive Licensees May Modify, How Modifications Affect Exclusivity Scope, and Required Documentation

This guide answers the most common questions exclusive licensees ask about modifying licensed formulas. It clarifies exactly which changes are permitted without NuCoreBio approval, which require written consent, which are prohibited, and how each type of modification affects your exclusivity rights and scope. Understanding these rules protects your investment and prevents unintentional breach of your Exclusive License Agreement.

THE GUIDING PRINCIPLE OF MODIFICATION RIGHTS

THE CORE PRINCIPLE: NuCoreBio licenses Formula IP — a scientifically validated combination of ingredients at specific doses with documented clinical evidence. Modifications that preserve the clinical evidence base are generally approved. Modifications that dilute it, substitute key actives, or effectively create a different product are restricted. This protects YOU as much as NuCoreBio — your brand's efficacy claims rest on the formula's clinical foundation.

— CHAPTER 1

The Three Categories of Modifications

All possible modifications to a licensed NuCoreBio formula fall into one of three categories, each with different approval requirements and exclusivity implications.

Category	Type of Modification	NuCoreBio Approval	Exclusivity Effect	Response Time
Category A (Free Modifications)	Excipients, capsule colour, bottle size, label language, serving instructions, packaging format (capsule→sachet same dose)	NO approval needed — notify NuCoreBio within 30 days	NO effect on exclusivity scope. Your exclusive territory remains unchanged.	N/A — just notify
Category B (Approved Modifications)	Active ingredient dose adjustments (±20% of spec), addition of non-competing supportive ingredients, reformulation for market compliance (e.g. remove NMN for EU), change dosage form with same actives	Written approval required BEFORE implementation	MAY expand exclusivity scope to cover new ingredient(s) in territory, with mutual agreement	NuCoreBio responds within 10 business days
Category C (Restricted Modifications)	Substituting a key active with a different ingredient, reducing a key active below 75% of specification dose, combining this formula with another licensed formula without consent, removing more than one active from the core formula	PROHIBITED without full renegotiation and new license schedule	If implemented without approval, may trigger material breach and license termination	Requires commercial renegotiation — not a standard approval process

— CHAPTER 2

Category A — Free Modifications (No Approval Needed)

The following modifications may be made freely. You simply notify NuCoreBio in writing within 30 days of implementation. No approval is required, and your exclusivity terms are unaffected.

Modification Type	Examples	Notification Requirement	Exclusivity Impact
Excipient changes	Swap rice flour filler for microcrystalline cellulose; change flow agent from magnesium stearate to calcium stearate	Written notification within 30 days. New excipient must be food/supplement grade.	None — excipients are not part of the licensed Formula IP
Capsule shell changes	Switch from gelatin to HPMC (vegan); change capsule colour or size (same fill weight)	Notify within 30 days. New capsule spec provided to NuCoreBio.	None — capsule shell is not licensed Formula IP
Serving format changes	Combine 2-capsule serving into 1 large capsule at same total dose; same formula in sachet format	Notify within 30 days. COA must still verify same active content.	None — delivery format not part of Formula IP
Bottle/packaging changes	Change from HDPE to glass; change from 60-count to 90-count; add child-resistant cap	Notify within 30 days.	None
Label language / market translation	Translate label to French, German, Spanish, Mandarin etc.	Notify within 30 days. Translated label sent for records.	None — label content not licensed IP
Brand name change	Rename your product from "TestoMax" to "VitalForce Pro" on same formula	Notify within 30 days. Your brand IP is yours.	None — NuCoreBio has no interest in your brand name
Serving size instructions	Change from "2 caps once daily" to "1 cap AM, 1 cap PM" (same total daily dose)	Notify within 30 days.	None
Flavour/sweetener changes (powders)	Change from vanilla to unflavored; add stevia vs sucralose in a powder formula	Notify within 30 days. Flavour system not licensed IP.	None — provided active ingredient content unchanged

HOW TO NOTIFY FOR CATEGORY A CHANGES

NOTIFICATION PROCESS FOR CATEGORY A: Send a brief email to Mc5896538@outlook.com with subject "Formula Modification Notice — [Formula Code] — Category A" and describe the change. No response is required from NuCoreBio, but we will confirm receipt within 5 business days. Keep all notification records as part of your license compliance file.

— CHAPTER 3

Category B — Approved Modifications (Written Consent Required)

The following modifications require NuCoreBio's prior written approval. Submit a Modification Request Form (available from NuCoreBio) describing the proposed change, the reason, and any supporting data. NuCoreBio responds within 10 business days. Implementing a Category B modification before receiving written approval constitutes a material breach of the Exclusive License Agreement.

Modification Type	Common Reason	Approval Criteria	Exclusivity Effect	Typical Outcome
Active ingredient dose adjustment (±20% of specification)	Local regulatory dose limits; consumer preference; cost optimization	New dose must still be within published clinical evidence range (MED threshold). COA must verify adjusted content. Stability re-verification may be required.	None — territory exclusivity unchanged. New spec becomes the licensed spec for your territory.	Usually approved within 10 days if clinically justified
Addition of non-competing supportive ingredient	Add Vitamin D3 to male T-support formula; add Hyaluronic Acid to collagen formula	New ingredient must not: (a) create a Novel Food issue in your territory; (b) create a drug interaction warning; (c) be a NuCoreBio proprietary ingredient already licensed to another party in your territory.	May expand your licensed formula scope. NuCoreBio may offer to add the ingredient to the master formula IP — beneficial for both parties.	Usually approved. New ingredient added to Schedule C of your license.
Active removal for regulatory compliance	Remove NMN from EU version (Novel Food); remove epimedium from German version; reduce high-dose B6 for UK compliance	Must demonstrate specific regulatory requirement in writing. Must confirm remaining formula still meets minimum efficacy threshold. Removed ingredient creates a market-specific formula variant.	Exclusivity covers the modified variant in your territory. Original formula exclusivity scope unchanged for non-affected markets.	Always approved when regulatory necessity is documented
Dosage form change (same actives, different delivery)	Convert capsule formula to powder sachet or gummy format for different consumer segment	New form must: (a) deliver same active content per serving; (b) pass stability testing in new form; (c) maintain Bio-Speed™ delivery characteristics if applicable.	Exclusivity extends to the new dosage form version in your territory. New form becomes a licensed variant.	Usually approved. Stability testing may be required for new form.

Modification Type	Common Reason	Approval Criteria	Exclusivity Effect	Typical Outcome
MAVC increase request (by licensee)	Licensee performing above MAVC and wants credit; wants to lock out competitors more aggressively by committing higher volume	NuCoreBio approves all MAVC increases. Higher MAVC = stronger exclusivity protection.	Stronger exclusivity signal. NuCoreBio may offer reduced royalty or extended term.	Always approved — benefits both parties

— CHAPTER 4

Category C — Restricted Modifications (Prohibited Without Renegotiation)

The following modifications are NOT permitted under a standard Exclusive License Agreement. They effectively create a different product, dilute the clinical evidence base, or conflict with NuCoreBio's IP rights. Implementing these changes without renegotiation constitutes a material breach that may result in license termination.

Restricted Modification	Why It Is Restricted	What To Do Instead
Substituting a key active with a chemically different ingredient (e.g. replacing KSM-66 Ashwagandha with a different adaptogen)	The clinical evidence supporting the formula is built on specific ingredient identities and standardisation. A substitution effectively creates a new, unlicensed formula. NuCoreBio cannot guarantee efficacy or safety claims for a substituted formula.	Apply for a new license for a different NuCoreBio formula that includes your preferred ingredient. Or commission NuCoreBio to develop a custom formula with your preferred actives.
Reducing a key active below 75% of specification dose (more than a ±20% adjustment)	Below 75% of clinical dose, the ingredient may fall below the Minimum Effective Dose (MED). Any efficacy claims become unsupported. This exposes you to regulatory and consumer liability.	If cost reduction is the goal, discuss it with NuCoreBio — we may be able to achieve savings through sourcing optimisation without changing the specification. Do not sacrifice clinical integrity for short-term cost savings.
Combining two licensed formulas without consent (e.g. merging your T-support and cognitive formulas into one)	Combined formulas create new IP not covered by either original license. May create interactions not validated. MAVC tracking becomes unclear.	Apply for a new combination formula license. NuCoreBio can assess synergy, validate the combination, and create a new licensed formula covering the combined product.
Sharing the formula with a third-party manufacturer not approved by NuCoreBio	Breach of confidentiality — Formula IP (concentrations, specifications) must not be disclosed to unapproved parties. Unapproved manufacturers may not maintain specification integrity.	Submit a Manufacturer Approval Application to NuCoreBio. NuCoreBio reviews and approves qualified GMP manufacturers within 30 days.
Selling or transferring the formula specification to a competitor	Direct breach of IP ownership and confidentiality provisions. Exclusive license grants a right to USE the formula, not to sell or transfer the IP.	If you wish to transfer the formula as part of a business sale, follow the change-of-control procedure in Article 9 of the Exclusive License Agreement.

CONSEQUENCES OF UNAUTHORISED CATEGORY C MODIFICATIONS

IMPORTANT: Implementing a Category C modification without prior NuCoreBio renegotiation is a material breach of the Exclusive License Agreement. NuCoreBio reserves the right to terminate the agreement with immediate effect if a Category C modification is discovered during audit or through COA review. License fees paid are non-refundable upon breach termination.

— CHAPTER 5

Documentation Requirements for All Modifications

Proper documentation protects you in regulatory audits, consumer disputes, and investor due diligence. For every modification — even Category A — maintain a complete record.

Document Required	Category A	Category B	Category C (Restricted)	Where to File
Written notification email to NuCoreBio	YES — within 30 days	YES — before implementation	N/A (prohibited)	Your license compliance file + email records
NuCoreBio written approval / rejection	Not required	YES — mandatory	N/A	License amendment file
Updated Formula Specification Sheet (Schedule C)	If excipient change affects spec	YES — updated by NuCoreBio	N/A	License schedule archive
Updated COA reflecting modification	YES — first batch after change	YES — first batch after approval	N/A	Quality management system
Stability data for modified formula	Not required for minor changes	Required if dosage form changed or active adjusted >10%	N/A	Technical dossier
Label amendment proof	Notify if label changes	New label reviewed by NuCoreBio (for claim accuracy)	N/A	Regulatory file
License Amendment document	Not required	Required formaterial modifications	Requires new agreement	Executed agreement archive

MODIFICATION REQUEST PROCESS

HOW TO SUBMIT A CATEGORY B MODIFICATION REQUEST: 1. Email Mc5896538@outlook.com — Subject: "Modification Request — [Formula Code] — [Territory]" 2. Describe the proposed change clearly: what is changing, what it was before, what it will be after. 3. State the reason (regulatory, commercial, consumer preference). 4. Attach any supporting data (regulatory guidance, clinical reference, stability concern). 5. NuCoreBio will respond within 10 business days with: Approval / Conditional Approval / Rejection + reason. 6. Do NOT implement the modification until written approval is received.

CONTACT US BEFORE MODIFYING

QUESTIONS ABOUT YOUR MODIFICATION RIGHTS? Our R&D; and licensing team is available to discuss any proposed modification before you submit a formal request. Email: Mc5896538@outlook.com | WhatsApp: +86 15866920149 Reference: NCB-FMR-053 · v2.0 · 2026 · NuCoreBio Technology Co., Ltd.